Program
suzetrigine
Also written as “Suzetrigine”, “VX-548” and “SUZ”.
Its studies are mostly in Pain · Acute Pain · Neuralgia · Radiculopathy, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Vertex Pharmaceuticals | 263 open or running | phase 4since Mar 19, 2025 | Jul 15, 2021 | Jan 25, 2027phase 3 · NCT06696443 |
| Latigo Biotherapeutics | 10 open or running | early phase 1since May 6, 2025 | May 6, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 10 studies since Jul 15, 2021.
- Jan 19, 2023Phase 1 study in PainVertex Pharmaceuticals · NCT05704556 · 38 enrolled · United States
- Apr 5, 20232 phase 1 studies in PainVertex Pharmaceuticals · NCT05818852, NCT05851157
- Dec 10, 2023Phase 2 study in Painful Lumbosacral RadiculopathyVertex Pharmaceuticals · NCT06176196 · 218 enrolled · United States
- Mar 21, 2024Phase 1 study in PainVertex Pharmaceuticals · NCT06336096 · 48 enrolled · United States
- May 14, 2024Phase 1 study in PainVertex Pharmaceuticals · NCT06420765 · 92 enrolled · United Kingdom
- Sep 30, 2024Phase 3 study in Diabetic Peripheral Neuropathic PainVertex Pharmaceuticals · NCT06628908 · 1,100 planned · United States
- Nov 15, 2024Phase 3 study in Diabetic Peripheral Neuropathic PainVertex Pharmaceuticals · NCT06696443 · 455 enrolled · United States
- Feb 5, 20252 phase 1 studies in PainVertex Pharmaceuticals · NCT06820307, NCT06834009
- Mar 19, 20252 phase 4 studies in Acute PainVertex Pharmaceuticals · NCT06887972, NCT06887959
- May 6, 2025Latigo Biotherapeutics's first study: early phase 1 study in Pain DetectionNew to Latigo BiotherapeuticsLatigo Biotherapeutics · NCT06972212 · 20 enrolled · New Zealand
- Nov 13, 2025Phase 3 study in Diabetic Peripheral Neuropathic PainVertex Pharmaceuticals · NCT07231419 · 734 planned · United States
- Jan 23, 2026Phase 1 study in PainVertex Pharmaceuticals · NCT07378865 · 13 enrolled · United States
- Apr 13, 2026Phase 4 study in PainVertex Pharmaceuticals · NCT07538570 · 66 enrolled · United States
- Apr 29, 2026Phase 1 study in PainVertex Pharmaceuticals · NCT07570069 · 18 enrolled · United States
Ahead
- Jan 25, 2027Primary completion: phase 3 study in Diabetic Peripheral Neuropathic PainVertex Pharmaceuticals · NCT06696443
- Apr 6, 2027Primary completion: phase 3 study in Diabetic Peripheral Neuropathic PainVertex Pharmaceuticals · NCT07231419
- May 31, 2027Primary completion: phase 3 study in Diabetic Peripheral Neuropathic PainVertex Pharmaceuticals · NCT06628908
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 27 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07570069Pain · United States | 1 | Completed | Vertex Pharmaceuticals | Jul 16, 2026 | 18 |
| NCT07538570Pain · United States | 4 | Completed | Vertex Pharmaceuticals | Oct 12, 2026 | 66 |
| NCT07378865Pain · United States | 1 | Completed | Vertex Pharmaceuticals | Aug 17, 2026 | 13 |
| NCT07231419Diabetic Peripheral Neuropathic Pain · United States | 3 | Recruiting | Vertex Pharmaceuticals | Apr 6, 2027 | 734 |
| NCT06972212Pain Detection · New Zealand | Early 1 | Completed | Latigo Biotherapeutics | Jun 28, 2025 | 20 |
| NCT06887972Acute Pain · United States | 4 | Completed | Vertex Pharmaceuticals | Oct 24, 2025 | 100 |
| NCT06887959Acute Pain · United States | 4 | Completed | Vertex Pharmaceuticals | Oct 27, 2025 | 47 |
| NCT06834009Pain · United States | 1 | Completed | Vertex Pharmaceuticals | Apr 24, 2025 | 10 |
| NCT06820307Pain · United States | 1 | Completed | Vertex Pharmaceuticals | Apr 29, 2025 | 50 |
| NCT06696443Diabetic Peripheral Neuropathic Pain · United States | 3 | Active, not recruiting | Vertex Pharmaceuticals | Jan 25, 2027 | 455 |
| NCT06628908Diabetic Peripheral Neuropathic Pain · United States | 3 | Recruiting | Vertex Pharmaceuticals | May 31, 2027 | 1,100 |
| NCT06420765Pain · United Kingdom | 1 | Completed | Vertex Pharmaceuticals | Mar 22, 2025 | 92 |
| NCT06336096Pain · United States | 1 | Completed | Vertex Pharmaceuticals | Jun 19, 2024 | 48 |
| NCT06176196Painful Lumbosacral Radiculopathy · United States | 2 | Completed | Vertex Pharmaceuticals | Oct 2, 2024 | 218 |
| NCT05851157Pain · United States | 1 | Completed | Vertex Pharmaceuticals | Oct 30, 2023 | 73 |
| NCT05818852Pain · United States | 1 | Completed | Vertex Pharmaceuticals | Jun 12, 2023 | 72 |
| NCT05704556Pain · United States | 1 | Completed | Vertex Pharmaceuticals | Mar 30, 2024 | 38 |
| NCT05661734Pain · United States | 3 | Completed | Vertex Pharmaceuticals | Dec 12, 2023 | 258 |
| NCT05660538Diabetic Peripheral Neuropathy · United States | 2 | Completed | Vertex Pharmaceuticals | Oct 12, 2023 | 194 |
| NCT05635110Pain · Australia | 1 | Completed | Vertex Pharmaceuticals | Jun 8, 2023 | 31 |
| NCT05560464Pain · United States | 1 | Completed | Vertex Pharmaceuticals | Jul 24, 2023 | 36 |
| NCT05558410Acute Pain · United States | 3 | Completed | Vertex Pharmaceuticals | Aug 25, 2023 | 1,118 |
| NCT05553366Acute Pain · United States | 3 | Completed | Vertex Pharmaceuticals | Dec 15, 2023 | 1,075 |
| NCT05541471Pain · United States | 1 | Completed | Vertex Pharmaceuticals | Apr 16, 2023 | 37 |
| NCT05455502Pain · United States | 1 | Completed | Vertex Pharmaceuticals | Sep 17, 2022 | 24 |
| NCT05034952Acute Pain · United States | 2 | Completed | Vertex Pharmaceuticals | Dec 5, 2021 | 303 |
| NCT04977336Acute Pain · United States | 2 | Completed | Vertex Pharmaceuticals | Feb 17, 2022 | 274 |
How it is read
Names in the registry
- “Suzetrigine”, 13 entries
- “VX-548”, 11 entries
- “SUZ”, 2 entries
- “suzetrigine 100mg”, 1 entry
- “Suzetrigine (SUZ)”, 1 entry
Codes read as this program: VX548.
Conditions, from the studies’ own filings
- Pain, 16 studies
- Acute Pain, 6 studies
- Neuralgia, 3 studies
- Radiculopathy, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.